Target Trial Emulation brings the logic of randomized trials into real-world data
Target Trial Emulation does not replace randomized controlled trials, but it applies their logic and rigor to real-world data analysis.
Latest News
Current topics and our latest news from the world of pharmaceuticals, healthcare and research. Make sure to follow us on LinkedIn to stay up-to-date!
Latest articles
-
-
Data Team is the Backbone of Medaffcon, Ensuring the Reliability of Research Results
The data team keeps Medaffcon's research projects on track and ensures that the research findings are scientifically sound. At the heart of the team’s work is the processing and analysis of patient data, particularly in Real-World Evidence (RWE) studies.
-
Sweden’s TLV Updates Reimbursement Model for Rare Diseases
Sweden has introduced a new reimbursement model for orphan drugs, likely to increase treatment options for rare diseases. At the same time, pharmaceutical companies are now expected to provide local evidence.
-
Medaffcon Presented Insights from Finnish Real-World Data at European Lung Cancer Congress
Medaffcon's European Lung Cancer Congress (ELCC) poster showcased key findings from a recent study on non-small cell lung cancer (NSCLC).
-
An Experienced Researcher seeks answers for their clients
Johan Rehnberg started working as a Scientific Advisor at Medaffcon’s Swedish office in August 2024. He is a dynamic researcher who values opportunities to learn new things and develop his skills – opportunities that Medaffcon provides.
-
Medaffcon’s Machine Learning Algorithm Adapts to Various Research Needs
The algorithm was originally developed to extract smoking status from patient texts with purpose to analyze the effects of smoking on postoperative complications. Today, it is also being utilized in lung cancer research.
Most popular articles
-
Medaffcon Brings RWE from the Nordic Markets for Global Use
Medaffcon's operations in Sweden are well-established and growing, offering pharmaceutical companies RWE studies and Market Access services delivered by Data Scientists, Market Access experts, and RWE specialists working together.
-
Medaffcon is Preparing to Conduct RWE Studies in Neurology and Psychiatry
In the coming years, breakthroughs in neurological and psychiatric drug research are expected to change treatment practices and significantly improve patients’ quality of life.
-
EHDS makes Finland an even more attractive place for RWE research
Finland will become an even more attractive place for conducting RWE (real-world evidence) research when it becomes a seamless part of the European Health Data Space (EHDS). Thus, health data can be used more efficiently across the European Union (EU), and datasets can be combined on an EU-wide basis.
-
Medaffcon answers call for its solutions-oriented data approach in Sweden
Medaffcon has added Swedish healthcare registries to its capabilities as it continues to pursue growth and facilitate data utilisation by providing pharmaceutical companies access to rich and relevant healthcare data.
-
Finnish ecosystem supports the use of real world evidence (RWE)
Real World Evidence (RWE) ecosystem in Finland Real world data (RWD) is defined by FDA…
-
Pharmaceutical Pricing and Market Access of Medicine Products in Finland
Medicines in Finland are divided into medicines in ambulatory and hospital care. This article describes…